Holen Sie sich die Stockscreener-App
0.015
14.50%
0.0019
Handel nachbörslich:
.02
0.005
+33.33%
Vincerx Pharma Inc Aktie (VINC) Neueste Nachrichten
Enterprise value to EBITDA forward of Vincerx Pharma, Inc. – OTC:VINC - TradingView
Price to book forward of Vincerx Pharma, Inc. – OTC:VINC - TradingView
Vincerx Pharma, Inc. Revenue Breakdown – OTC:VINC - TradingView
Vincerx Pharma Inc Actuals & Estimates (OTC:VINC) - TradingView
Why Is Vincerx Pharma, Inc. (VINCU) Stock Down Today? - Meyka
Drug Transport Company Sued by Insurer Over Destroyed-Cells Case - Bloomberg Law News
Vincerx Pharma, Inc. Announces Additional Adjournment of - globenewswire.com
Vincerx Pharma | DEFA14A: Others - Moomoo
At a crossroads, biotechs are passing on reverse mergers in 2025 - Endpoints News
VINCERX PHARMA (VINC) Stock Price, News & Analysis - Stock Titan
VINC Stock Price and Chart — OTC:VINC - TradingView
Nasdaq to delist Vincerx Pharma by April 23 - Investing.com Australia
vincerx pharma cancels merger, initiates wind-down activities By Investing.com - Investing.com India
vincerx pharma cancels merger, initiates wind-down activities - Investing.com
Vincerx's final merger attempt collapses, leaving ADC biotech to wind down - Fierce Biotech
Financially struggling drugmaker's potential rescue falls apart. It now will wind down - bizjournals.com
Vincerx Pharma Inc. (VINC) reports earnings - qz.com
Vincerx, left in limbo by collapsed deal, moves to merge with AI company to escape cash crisis - Fierce Biotech
Cash-strapped Vincerx left mulling future after Oqory reverse merger falls apart - Fierce Biotech
Vincerx Pharma Announces Termination of Reverse Merger Term Sheet and Evaluation of Strategic Alternatives - Yahoo Finance
Vincerx Pharma, Inc. and Oqory, Inc. Highlight Promising Data for Oqory’s TROP2 Antibody Drug Conjugate, OQY-3258 - GlobeNewswire
Stock market news: Vincerx Pharma plunged by 95.86% while MiNK Therapeutics was down by 94.26% during mid day trading - Business Upturn
Vincerx Pharma To Carry Out 1-for-20 Reverse Stock Split On January 28th, 2025 - moomoo.com
Vincerx Pharma, Inc. Announces Reverse Stock Split - The Manila Times
Vincerx Pharma enters at-the-market equity offering deal - Investing.com
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates VINC, MHLD, NE - GuruFocus
Vincerx acquisition leads to C-suite shake-up—Chutes & Ladders - Fierce Biotech
Fierce Biotech Layoff Tracker 2024: Vincerx reduces workforce; Novartis lays off 330 staffers - Fierce Biotech
Vincerx Pharma Stock Rises On Proposed Merger With Oqory: Retail Remains Bullish - Asianet Newsable
Vincerx Pharma Enters into a Binding Term Sheet for a Strategic Merger with Oqory, Inc. - Yahoo Finance
Vincerx Pharma gets extension to meet Nasdaq listing criteria - Investing.com
ARMISTICE CAPITAL, LLC Expands Stake in Vincerx Pharma Inc - GuruFocus
Prosight Management, LP Reduces Stake in Vincerx Pharma Inc - GuruFocus
Vincerx Pharma Inc (VINC) Quarterly 10-Q Report - qz.com
VINC Stock Touches 52-Week Low at $0.51 Amid Market Challenges - Investing.com
Vincerx Reports Positive Initial Clinical Data from Ongoing - GlobeNewswire
Vincerx Pharma (NASDAQ: VINCU)Share Price - intelligentinvestor.com.au
Vincerx Pharma Reports Second Quarter 2024 Financial Results - GlobeNewswire
Vincerx Pharma Announces Proposed Underwritten Public Offering of Common Stock and Warrants - Investing News Network
Vincerx Pharma Announces Proposed Underwritten Public Offering of Common Stock and Warrants By Investing.com - Investing.com India
Vincerx Blames Stock Plunge On Overheated ADC Expectations - Citeline News & Insights
Why Is Vincerx Pharma (VINC) Stock Down 64% Today? - InvestorPlace
Vincerx Pharma Presents Positive Preliminary Phase 1 Data - GlobeNewswire
Vincerx to Host Virtual Investor Event Reviewing - GlobeNewswire
Vincerx To Report VIP236 Trial Data Next Month - RTTNews
Why Is Cancer Focused Penny Stock Vincerx Pharma Trading Higher Today? By Benzinga - Investing.com UK
Vincerx Pharma Announces Compelling Clinical Efficacy of - GlobeNewswire
Vincerx Pharma Reports Third Quarter 2023 Financial Results and Provides Corporate Update - GlobeNewswire
Ruth E. Stevens Net Worth (2026) - GuruFocus
Vincerx Pharma Doses First Patient in the Phase 1 Clinical Trial Evaluating VIP943 - GlobeNewswire
Vincerx Pharma, Inc. (VINC) Dividend History, Date, and Yield - CoinCodex
Biopharma Comebacks With Vincerx's Ahmed Hamdy, MD - Bioprocess Online
ARDS Stock Price and Chart — OTC:ARDS - TradingView
John C. Byrd Net Worth (2026) - gurufocus.com
Vincerx Pharma discovers new drug conjugates based on prodrugs of CDK9 inhibitors - BioWorld News
Vincerx Pharma Presents Preclinical Data on VIP924, a - GlobeNewswire
Vincerx Pharma, Inc. (VINC) Stock Forecast & Price Prediction 2026–2030 - CoinCodex
Vincerx Pharma Announces Poster Presentations at the - GlobeNewswire
Xiaoming Zhang Net Worth (2026) - GuruFocus
David Efraim Rosen Net Worth (2026) - GuruFocus
Vincerx Pharma to Participate at the SVB Securities Global Biopharma Conference - GlobeNewswire
Vincerx Pharma Announces FDA Safe to Proceed Letter for - GlobeNewswire
Vincerx Pharma Reports Second Quarter 2022 Financial Results and Provides a Corporate Update - GlobeNewswire
Vincerx Pharma : Statement of Changes in Beneficial Ownership (Form 4) - marketscreener.com
Vincerx Pharma Announces Poster Presentation at the - GlobeNewswire
Vincerx Pharma Publishes Preclinical Data Demonstrating - GlobeNewswire
VINC Stock Price, Quote & Chart | VINCERX PHARMA INC (NASDAQ:VINC) - ChartMill
Vincerx Pharma Stock Short Interest Report | OTC:VINC - Benzinga
Vincerx Pharma Announces $50 Million Private Placement - GlobeNewswire
Vincerx Pharma, Inc. (VINC) Latest Stock News & Headlines - Yahoo! Finance Canada
Vincerx Pharma, Inc. (VINC) stock price, news, quote and history - Yahoo Finance Singapore
Vincerx—next-generation antibody–drug conjugates with enhanced therapeutic windows - Nature
Vincerx Gets Law Chief From Pillsbury Firm That Advised Biotech - Bloomberg Law News
Vincerx Pharma to Participate in the 10th Annual SVB Leerink Global Healthcare Conference - GlobeNewswire
0.05%
1.96%
Kapitalisierung:
|
Volumen (24h):